Comments
Glenmark Pharmaceuticals has completed Phase-I clinical trials of its new molecule, GRC 15300, being developed for treatment of pain.
Glenmark Pharmaceuticals SA, the company’s wholly owned subsidiary, has successfully completed Phase-I trials of GRC 15300, a first-in-class inhibitor for treatment of pain, Glenmark Pharma said in a statement today.
“GRC 15300 is worldwide the first TRPV3 inhibitor which has successfully finished a Phase-I study. It is an exciting target and we are looking forward to continued development on the programme,” the company Chairman and Managing Director, Mr Glenn Saldanha, said.
Glenmark has completed Phase-I dosing and analysis of the study data of GRC 15300 in the UK and the drug has been well tolerated, the company said, adding that it has plans to “initiate clinical proof of concept studies in neuropathic pain’’.
Sanofi has licensed the rights to all therapeutic indications, the company said.
“GRC 15300 is an inhibitor of the TRPV3 (transient receptor potential cation channel, subfamily V, member 3). This is the first TRPV3 inhibitor which entered clinical trials,” it added.
Glenmark has eight novel molecules in various stages of development and is primarily focused on the areas of inflammation and pain.
Meanwhile, the company shares were being quoted at Rs 321.45 in the afternoon trade on the Bombay Stock Exchange, up 2.67 per cent from its previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.